Use of #proton pump inhibitors to treat persistent #throat symptoms: multicentre, double blind, randomised, placebo controlled trial

To assess the use of proton pump inhibitors (PPIs) to treat persistent throat symptoms.. ..Random blinded allocation (1:1) to either 30 mg lansoprazole twice daily or matched placebo twice daily for 16 weeks. Main outcome measures Primary outcome was symptomatic response at 16 weeks measured using the total reflux symptom index (RSI) score. Secondary outcomes included symptom response at 12 months, quality of life, and … Continue reading Use of #proton pump inhibitors to treat persistent #throat symptoms: multicentre, double blind, randomised, placebo controlled trial

Rate This

The influence of #proton pump inhibitor therapy on the outcome of #infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies

In treating patients with inflammatory bowel disease (IBD), how concomitant medications influence the response to infliximab is largely unexplored. We aim to evaluate whether proton pump inhibitors (PPIs) affect the response to infliximab therapy in patients with IBD.. Among the five randomised controlled studies, there were 889 and 147 patients on infliximab with and without PPI therapy, respectively. Patients on PPI were older, more likely … Continue reading The influence of #proton pump inhibitor therapy on the outcome of #infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies

Rate This

Efficacy and safety of gastrointestinal #bleeding prophylaxis in critically #ill patients: an updated systematic review and network meta-analysis of randomized trials

Motivated by a new randomized trial (the PEPTIC trial) that raised the issue of an increase in mortality with proton pump inhibitors (PPIs) relative to histamine-2 receptor antagonists (H2RAs), we updated our prior systematic review and network meta-analysis (NMA) addressing the impact of pharmacological gastrointestinal bleeding prophylaxis in critically ill patients. Seventy-four trials enrolling 39 569 patients proved eligible. Both PPIs (risk ratio (RR) 1.03, … Continue reading Efficacy and safety of gastrointestinal #bleeding prophylaxis in critically #ill patients: an updated systematic review and network meta-analysis of randomized trials

Rate This

Association Between Acute #Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses

An increased risk of acute bacterial enteric infections has been reported among patients receiving proton pump inhibitor (#PPI) therapy. The risk of acute gastroenteritis (AGE) of viral origin associated with continuous PPI exposure has been less studied ..At least 1 AGE epidemic episode was identified in 3131 patients (1.3%) receiving PPI therapy and in 4327 patients (0.7%) not receiving PPI therapy. The adjusted relative risk … Continue reading Association Between Acute #Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses

Rate This

Randomized Trial of Medical versus Surgical Treatment for Refractory #Heartburn

..Heartburn that persists despite proton-pump inhibitor ( #PPI ) treatment is a frequent clinical problem with multiple potential causes. Treatments for PPI-refractory heartburn are of unproven efficacy and focus on controlling gastroesophageal reflux with reflux-reducing medication (e.g., baclofen) or antireflux surgery or on dampening visceral hypersensitivity with neuromodulators (e.g., desipramine). Prerandomization procedures excluded 288 patients: 42 had relief of their heartburn during the 2-week omeprazole … Continue reading Randomized Trial of Medical versus Surgical Treatment for Refractory #Heartburn

Rate This